CDEK
← All drugs Report issue

indoximod

Small moleculeexperimental

1-Methyltryptophan is a chemical compound that is an inhibitor of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase. It is a chiral compound that can exist as both D- and L-enantiomers. — Wikipedia

Clinical trial activity

20 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
15
Phase 2
9
Phase 3
1
Phase 4
0

Earliest trial started Oct 1, 2007 (NCT00567931)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cn1cc(C[C@@H](N)C(=O)O)c2ccccc21
Mol. weight
218.26 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1-methyl-dl-trp
  • 1-methyl-d-tryptophan
  • 1-methyl-d-tryptophan
  • 1-methyl-d-tryptophan
  • 1-methyltryptophan
  • (2r)-2-amino-3-(1-methyl-1h-indol-3-yl)propanoic acid
  • (2r)-2-amino-3-(1-methyl-1h-indol-3-yl)propanoic acid
  • alpha-(11c)methyl-l-tryptophan
  • alpha-(14c)methyl-tryptophan
  • alpha-methyl-l-tryptophan
  • alpha-methyltryptophan
  • alpha-methyltryptophan
  • alpha-methyltryptophan
  • alpha-methyltryptophan, (d)-isomer
  • alpha-methyltryptophan, (dl)-isomer
  • alpha-methyltryptophan, (-)-isomer
  • alpha-methyltryptophan, (+)-isomer
  • alpha-methyltryptophan, (l)-isomer
  • d-(+)-1-methyltryptophan
  • d-(+)-1-methyltryptophan
  • d-1-methyltryptophan
  • d-1-methyltryptophan
  • d-1-methyltryptophan
  • d-1mt
  • d-1mt
  • d-1mt
  • indoximod
  • indoximod
  • indoximod
  • indoximod
  • indoximod
  • nlg802

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05469490Phase 1Oct 31, 2022Lumos Pharma, University of Pittsburgh
NCT05106296Phase 1Feb 28, 2022Augusta University
NCT04049669Phase 2Sep 30, 2019Augusta University, Emory University
NCT03852446Early Phase 1 (Phase 1)Mar 5, 2018NewLink Genetics Inc
NCT03301636Phase 2/Phase 3 (Phase 3)Dec 8, 2017NewLink Genetics Inc
NCT03372239Phase 1Nov 21, 2017NewLink Genetics Inc
NCT03164603Phase 1May 1, 2017NewLink Genetics Inc
NCT02835729Phase 1/Phase 2 (Phase 2)Jul 1, 2016NewLink Genetics Inc
NCT02460367Phase 1/Phase 2 (Phase 2)Jan 1, 2016NewLink Genetics Inc
NCT02502708Phase 1Oct 1, 2015NewLink Genetics Inc
NCT02077881Phase 1/Phase 2 (Phase 2)Aug 1, 2014NewLink Genetics Inc
NCT02073123Phase 1/Phase 2 (Phase 2)Jul 1, 2014NewLink Genetics Inc
NCT02052648Phase 1/Phase 2 (Phase 2)Mar 1, 2014NewLink Genetics Inc
NCT01792050Phase 2Feb 1, 2013NewLink Genetics Inc
NCT01302821N/AJan 1, 2013National Cancer Institute (NCI), University of South Florida
NCT01560923Phase 2Oct 1, 2012University of Minnesota
NCT01191216Phase 1Sep 1, 2010National Cancer Institute (NCI), University of South Florida
NCT01042535Phase 1/Phase 2 (Phase 2)Dec 28, 2009National Cancer Institute (NCI), University of South Florida
NCT00739609Phase 1Aug 1, 2008NewLink Genetics Inc
NCT00567931Phase 1Oct 1, 2007National Cancer Institute (NCI), University of South Florida
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NewLink Genetics IncFor profit121232008
National Cancer Institute (NCI)Government4232007
University of South FloridaAcademic/Hospital4232007
Augusta UniversityAcademic/Hospital2222019
Emory UniversityAcademic/Hospital1012019
Lumos PharmaFor profit1012022
University of MinnesotaAcademic/Hospital1112012
University of PittsburghAcademic/Hospital1112022
8 organizations
Page 1 / 1